Grimm, S. E., Fayter, D., Ramaekers, B. L. T., Petersohn, S., Riemsma, R., Armstrong, N., . . . Joore, M. A. (2019). Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics.
Chicago Stili AlıntıGrimm, Sabine E., et al. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Pharmacoeconomics 2019.
MLA AlıntıGrimm, Sabine E., et al. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Pharmacoeconomics 2019.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..